NiKang Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
41
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
26
NiKang Therapeutics General Information
Description
Operator of a biotechnology company intended to discover and develop innovative small-molecule oncology medicines. The company focuses on combating cancer and helping patients with unmet medical needs through deep insights into disease biology and molecular pathways, enabling healthcare providers to treat their patients and improve their lives.
Contact Information
Website
www.nikangtx.comCorporate Office
- 200 Powder Mill Road
- Building E500
- Wilmington, DE 19803
- United States
Corporate Office
- 200 Powder Mill Road
- Building E500
- Wilmington, DE 19803
- United States
NiKang Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 | ||||
| 4. Later Stage VC (Series C) | 19-May-2021 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series B) | 09-Sep-2020 | Completed | Clinical Trials - General | |||
| 2. Debt - PPP | 28-Apr-2020 | $236K | $10M | Completed | Clinical Trials - General | |
| 1. Early Stage VC (Series A) | 04-Dec-2017 | $10M | $10M | Completed | Startup |
NiKang Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B2 | ||||||||
| Series B1 | 16,071,426 | $0.000100 | $2.8 | $2.8 | 1x | $2.8 | 20.49% | |
| Series A | 10,000,000 | $0.000100 | $1 | $1 | 1x | $1 | 12.75% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
NiKang Therapeutics Comparisons
Industry
Financing
Details
NiKang Therapeutics Competitors (3)
One of NiKang Therapeutics’s 3 competitors is Vividion Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vividion Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Cybrexa Therapeutics | Venture Capital-Backed | New Haven, CT |
NiKang Therapeutics Patents
NiKang Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026212994-A1 | Bifunctional compounds containing multi substituted alkylsulfonyl linker for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway | Pending | 31-Mar-2025 | ||
| WO-2026198338-A1 | Bifunctional compounds containing substituted alkylsulfonyl linker moiety for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway | Pending | 19-Mar-2025 | ||
| WO-2026011344-A1 | Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway | Pending | 10-Jul-2024 | ||
| WO-2025240536-A1 | Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway | Pending | 15-May-2024 | ||
| WO-2025235261-A1 | Bifunctional compounds containing 2,4,5-substituted pyrimidine derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway | Pending | 07-May-2024 | A61K31/506 |
NiKang Therapeutics Signals
NiKang Therapeutics Investors (26)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ally Bridge Group | Growth/Expansion | Minority | ||
| BlackRock | Asset Manager | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority | ||
| EcoR1 Capital | Venture Capital | Minority | ||
| Invus (Private Equity) | PE/Buyout | Minority |
NiKang Therapeutics FAQs
-
When was NiKang Therapeutics founded?
NiKang Therapeutics was founded in 2017.
-
Where is NiKang Therapeutics headquartered?
NiKang Therapeutics is headquartered in Wilmington, DE.
-
What is the size of NiKang Therapeutics?
NiKang Therapeutics has 41 total employees.
-
What industry is NiKang Therapeutics in?
NiKang Therapeutics’s primary industry is Drug Discovery.
-
Is NiKang Therapeutics a private or public company?
NiKang Therapeutics is a Private company.
-
What is NiKang Therapeutics’s current revenue?
The current revenue for NiKang Therapeutics is .
-
How much funding has NiKang Therapeutics raised over time?
NiKang Therapeutics has raised $260M.
-
Who are NiKang Therapeutics’s investors?
Ally Bridge Group, BlackRock, Cormorant Asset Management, EcoR1 Capital, and Invus (Private Equity) are 5 of 26 investors who have invested in NiKang Therapeutics.
-
Who are NiKang Therapeutics’s competitors?
Vividion Therapeutics, Inovio Pharmaceuticals, and Cybrexa Therapeutics are competitors of NiKang Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process